Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPOR | P19235 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3363612 | 1.00 | EPOR (0.54) | EPORALDH1A1HSD17B10THRBCYP2C9 | |
| SCHEMBL83747 | 1.00 | EPOR (0.54) | EPORALDH1A1HSD17B10THRBCYP2C9 | |
| SCHEMBL10315701 | 0.89 | EPOR (0.53) | EPORALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL26720031 | 0.87 | TSHR (0.46) | EPORALDH1A1HSD17B10THRBCYP2C9 | |
| SCHEMBL3854880 | 0.87 | EPOR (0.54) | EPORALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL7763937 | 0.87 | EPOR (0.54) | EPORALDH1A1HSD17B10THRBCYP2C9 | |
| SCHEMBL3854879 | 0.87 | EPOR (0.54) | EPORALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL13064940 | 0.86 | L3MBTL1 (0.52) | EPORALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL14935460 | 0.86 | EPOR (0.53) | EPORALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL31489074 | 0.86 | L3MBTL1 (0.52) | EPORALDH1A1HSD17B10KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735424-A1 | PROCESSES FOR MAKING IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| CN-120091811-A | Integrin inhibitors and their use in combination with other agents | 普利安特治疗公司 | 2025-06-03 | — | — | CN | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4551204-A2 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | Pliant Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20090005433-A1 | Fluorinated Compounds | NPS PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005433-A1 | Fluorinated Compounds | NPS PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20080269284-A1 | Compounds and Methods for Treating Dyslipidemia | ELI LILLY AND COMPANY (US) | 2008-10-30 | — | — | US | disclosed |
| EP-1963277-A1 | FLUORINATED COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008070994-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. (CA) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008070994-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. (CA) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007076306-A1 | FLUORINATED COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007076306-A1 | FLUORINATED COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1761521-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006012093-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EPOR 2910/4885ALDH1A1 2776/4885HSD17B10 2107/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EPOR 2910/4885ALDH1A1 2776/4885HSD17B10 2107/4885 |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | EPOR 700/4885ALDH1A1 3476/4885HSD17B10 4519/4885 |
| US-20090005433-A1 | Fluorinated Compounds | CNR1, NPFFR1, AFF1 | EPOR 2120/4885ALDH1A1 1176/4885HSD17B10 3370/4885 |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | EPOR 637/4885ALDH1A1 3834/4885HSD17B10 4411/4885 |
| US-20080269284-A1 | Compounds and Methods for Treating Dyslipidemia | APOB, PCSK9, LIPC | EPOR 832/4885ALDH1A1 1525/4885HSD17B10 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.